Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neuropharmacology
2017 Feb 01;113Pt A:60-70. doi: 10.1016/j.neuropharm.2016.09.016.
Show Gene links
Show Anatomy links
Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder.
Huynh N
,
Arabian N
,
Naito A
,
Louie S
,
Jakowec MW
,
Asatryan L
,
Davies DL
.
???displayArticle.abstract???
Current pharmacotherapies for alcohol used disorder (AUD) are few and relatively ineffective illustrating the need for the development of new, effective medications. Using a translational approach, our laboratory reported that ivermectin, an FDA-approved, human and animal anti-parasitic agent, can significantly reduce ethanol intake in male and female mice across different drinking paradigms. Extending this line of investigation, the current paper investigated the utility of moxidectin (MOX), an analogue of ivermectin, to reduce ethanol intake. Notably, MOX is widely held to have lower neurotoxicity potential and improved margin of safety compared to ivermectin. Using a 24-h-two-bottle choice paradigm, MOX significantly reduced ethanol intake in a dose dependent manner in both male and female C57BL/6J mice, respectively (1.25-7.5 mg/kg) and (1.25-10 mg/kg). Further, multi-day administration of MOX (2.5 mg/kg; intraperitoneal injection) for 5 consecutive days significantly reduced ethanol intake in both the 24-h-two-bottle choice and Drinking-in-the-Dark paradigms in female mice. No overt signs of behavioral toxicity were observed. Notably in both male and female mice, MOX significantly reduced ethanol intake starting approximately 4 h post-injection. Using a Xenopus oocyte expression system, we found that MOX significantly potentiated P2X4 receptor (P2X4R) function and antagonized the inhibitory effects of ethanol on ATP-gated currents in P2X4Rs. This latter finding represents the first report of MOX having activity on P2X4Rs. In addition, MOX potentiated GABAA receptors, but to a lesser degree as compared to ivermectin supporting the hypothesis that MOX would be advantageous (compared to ivermectin) with respect to reducing contraindications. Overall, the results illustrate the potential for development of MOX as a novel pharmacotherapy for the treatment of AUD.
Asatryan,
Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders.
2014, Pubmed,
Xenbase
Asatryan,
Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders.
2014,
Pubmed
,
Xenbase
Asatryan,
Roles of ectodomain and transmembrane regions in ethanol and agonist action in purinergic P2X2 and P2X3 receptors.
2008,
Pubmed
,
Xenbase
Asatryan,
Ivermectin antagonizes ethanol inhibition in purinergic P2X4 receptors.
2010,
Pubmed
,
Xenbase
Balayssac,
Does inhibition of P-glycoprotein lead to drug-drug interactions?
2005,
Pubmed
Baoliang,
Pharmacokinetics of eprinomectin in plasma and milk following subcutaneous administration to lactating dairy cattle.
2006,
Pubmed
Belknap,
Voluntary consumption of ethanol in 15 inbred mouse strains.
1993,
Pubmed
Blednov,
Hybrid mice as genetic models of high alcohol consumption.
2010,
Pubmed
Bortolato,
Pharmacological insights into the role of P2X4 receptors in behavioural regulation: lessons from ivermectin.
2013,
Pubmed
Bouchery,
Economic costs of excessive alcohol consumption in the U.S., 2006.
2011,
Pubmed
Cotreau,
The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans.
2003,
Pubmed
Crabbe,
Preclinical studies of alcohol binge drinking.
2011,
Pubmed
Davies,
The role of GABAA receptors in mediating the effects of alcohol in the central nervous system.
2003,
Pubmed
Davies,
Ethanol sensitivity in ATP-gated P2X receptors is subunit dependent.
2002,
Pubmed
,
Xenbase
Davies,
Ethanol differentially affects ATP-gated P2X(3) and P2X(4) receptor subtypes expressed in Xenopus oocytes.
2005,
Pubmed
,
Xenbase
Dawson,
Anticonvulsant and adverse effects of avermectin analogs in mice are mediated through the gamma-aminobutyric acid(A) receptor.
2000,
Pubmed
,
Xenbase
Edwards,
Ivermectin: does P-glycoprotein play a role in neurotoxicity?
2003,
Pubmed
Ford,
Ethanol intake patterns in female mice: influence of allopregnanolone and the inhibition of its synthesis.
2008,
Pubmed
Grant,
The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002.
2004,
Pubmed
Guzzo,
Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.
2002,
Pubmed
Harris,
Pharmacotherapy of alcohol use disorders in the Veterans Health Administration.
2010,
Pubmed
Heilig,
Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms.
2006,
Pubmed
Janko,
Moxidectin has a lower neurotoxic potential but comparable brain penetration in P-glycoprotein-deficient CF-1 mice compared to ivermectin.
2013,
Pubmed
Johnson,
Medication treatment of different types of alcoholism.
2010,
Pubmed
Johnson,
Topiramate for treating alcohol dependence: a randomized controlled trial.
2007,
Pubmed
Kiki-Mvouaka,
Role of P-glycoprotein in the disposition of macrocyclic lactones: A comparison between ivermectin, eprinomectin, and moxidectin in mice.
2010,
Pubmed
Korth-Bradley,
Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin.
2012,
Pubmed
Lanusse,
Comparative plasma disposition kinetics of ivermectin, moxidectin and doramectin in cattle.
1997,
Pubmed
Lespine,
Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship.
2007,
Pubmed
Litten,
Medications development to treat alcohol dependence: a vision for the next decade.
2012,
Pubmed
Lowery,
CRF-1 antagonist and CRF-2 agonist decrease binge-like ethanol drinking in C57BL/6J mice independent of the HPA axis.
2010,
Pubmed
McBride,
Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents.
1998,
Pubmed
Ménez,
Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA(A) channel activity.
2012,
Pubmed
,
Xenbase
Neasta,
Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcohol-related disorders.
2010,
Pubmed
Omura,
Ivermectin: 25 years and still going strong.
2008,
Pubmed
Popova,
A point mutation in the ectodomain-transmembrane 2 interface eliminates the inhibitory effects of ethanol in P2X4 receptors.
2010,
Pubmed
,
Xenbase
Prichard,
Moxidectin and the avermectins: Consanguinity but not identity.
2012,
Pubmed
Rhodes,
Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice.
2005,
Pubmed
Roche,
A Pilot Study of the Safety and Initial Efficacy of Ivermectin for the Treatment of Alcohol Use Disorder.
2016,
Pubmed
Shan,
Ivermectin, an unconventional agonist of the glycine receptor chloride channel.
2001,
Pubmed
Sigel,
Structure, function, and modulation of GABA(A) receptors.
2012,
Pubmed
Spinosa,
Possible anxiolytic effects of ivermectin in rats.
2002,
Pubmed
Steensland,
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.
2007,
Pubmed
Wilcox,
Repeated binge-like ethanol drinking alters ethanol drinking patterns and depresses striatal GABAergic transmission.
2014,
Pubmed
Wolstenholme,
Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics.
2005,
Pubmed
Wyatt,
Contribution of P2X4 receptors to ethanol intake in male C57BL/6 mice.
2014,
Pubmed
Xiao,
Ethanol facilitates glutamatergic transmission to dopamine neurons in the ventral tegmental area.
2009,
Pubmed
Yamaguchi,
Amino acid residues of both the extracellular and transmembrane domains influence binding of the antiparasitic agent milbemycin to Haemonchus contortus AVR-14B glutamate-gated chloride channels.
2012,
Pubmed
Yardley,
Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder.
2015,
Pubmed
Yardley,
Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans.
2014,
Pubmed
Yardley,
Ivermectin reduces alcohol intake and preference in mice.
2012,
Pubmed
,
Xenbase
Yoneyama,
Voluntary ethanol consumption in 22 inbred mouse strains.
2008,
Pubmed
